Cardiology – Page 2

Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 Trial

By MedXY 07/02/2026

The TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year follow-up.

Cardiology news

Impact of Multidimensional Social Adversity on Mortality and Rehospitalization in People with HIV and Heart Failure

By MedXY 07/02/2026

This study explores how various social adversity domains affect mortality and rehospitalization risks in HIV-positive patients with heart failure, underscoring the importance of holistic social assessments for improving outcomes.

Cardiology Clinical Updates news Radiology

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics

By MedXY 07/02/2026

Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-term cardiac risks.

Cardiology Diabetes & Endocrinology news

Continuous Glucose Monitoring-Derived Time in Range Predicts Longitudinal Changes in Arterial Stiffness in Type 2 Diabetes

By MedXY 07/01/2026

This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascular risk management.

Cardiology Clinical Updates news

AAVrh.10hFXN Gene Therapy for Friedreich Ataxia Cardiomyopathy: Safety and Preliminary Efficacy in a Nonrandomized Clinical Trial

By MedXY 07/01/2026

This review synthesizes evidence from a pioneering nonrandomized trial demonstrating that intravenous AAVrh.10hFXN gene therapy is safe and may improve cardiac outcomes in Friedreich ataxia cardiomyopathy, highlighting translational advances in precision cardiac gene therapy.

Cardiology news Pathology & Lab Medicine/Bệnh học

Beyond Granulomas: Unraveling Cardiac Sarcoidosis with Spatial Proteomics

By MedXY 07/01/2026

Spatial proteomics reveals immune and metabolic heterogeneity in cardiac sarcoidosis, identifying new diagnostic protein signatures beyond granulomatous lesions.

Cardiology news Public Health

Decoding the Cardiovascular Risks of PM2.5 Components: Insights from a Half-Million Chinese Adults Cohort Study

By MedXY 07/01/2026

This large-scale study links specific PM2.5 components, especially chloride, black carbon, and sulfate, to increased long-term cardiovascular disease risk, emphasizing targeted pollution control for better heart health.

Cardiology news

Pulsed Field Ablation Versus Sham Procedure in Atrial Fibrillation: Insights from the PFA-SHAM Randomized Clinical Trial

By MedXY 07/01/2026

This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.

Cardiology Neurology news

Left Atrial to Ventricular Volume Ratio: A Novel Imaging Biomarker Enhancing Detection of Atrial Cardiopathy and Stroke Risk

By MedXY 06/28/2026

The left atrial to ventricular volume ratio (LA:LV ratio) emerges as a superior marker over left atrial volume index (LAVi) for atrial cardiopathy, showing stronger association with ischemic stroke risk, cognitive decline, and atrial fibrillation detection in large cohorts.

Cardiology Clinical Updates news

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

By MedXY 06/28/2026

The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten as a superior first-line therapy.

Cardiology news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY 06/28/2026

The FOREST-HCM long-term study confirms aficamten's efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Cardiology news

Long-Term Success of Combined Myectomy and Secondary Mitral Chordal Cutting in Obstructive Hypertrophic Cardiomyopathy

By MedXY 06/28/2026

This study demonstrates that septal myectomy combined with cutting of secondary mitral valve chordae delivers excellent long-term survival and symptom relief in obstructive hypertrophic cardiomyopathy patients unresponsive to medical therapy.

Cardiology news

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY 06/27/2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment and prevention strategies.

Cardiology news

Unveiling the Burden of Valvular Heart Disease Among Older Americans: Insights from the PREVUE-VALVE Study

By MedXY 06/26/2026

The PREVUE-VALVE study reveals a significant prevalence of moderate or greater valvular heart disease among U.S. adults aged 65-85, highlighting substantial public health implications and the value of decentralized echocardiographic screening.

Cardiology Clinical Updates news

Association of Common Ancestry-Enriched Variants With Cardiomyopathy and Arrhythmias: Insights From Genetic Studies in Individuals of African Ancestry

By MedXY 06/26/2026

Genetic variants enriched in individuals of African ancestry confer increased risk of cardiomyopathy and arrhythmias, with cardiovascular risk factors amplifying this risk. Large biobank studies enable reclassification of key variants and highlight the need for ancestry-specific genetic risk assessment.

Cardiology Emergency Medicine news

Evaluating Point-of-Care Ultrasound Accuracy for Right Ventricular Dysfunction in Pulmonary Embolism: A Comparative Analysis with Consultative Echocardiography

By MedXY 06/26/2026

This study assesses the accuracy of emergency physician-interpreted point-of-care ultrasound compared to cardiologist-interpreted consultative echocardiography for detecting right ventricular dysfunction in emergency patients with pulmonary embolism, revealing moderate sensitivity and specificity, with improved accuracy in moderate to severe cases.

Cardiology Internal Medicine news

Multilevel Stewardship to Optimize Antithrombotic Therapy in DOAC Users: Lessons from a Veterans Health Initiative

By MedXY 06/26/2026

A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.

Cardiology news Respiratory

Decoding Pulmonary Arterial Hypertension in Congenital Heart Disease: Latent Class Analysis Uncovers Distinct Risk Phenotypes and Treatment Insights

By MedXY 06/25/2026

Latent class analysis of 889 adult PAH-CHD patients identified unique phenogroups with distinct survival outcomes and treatment responses, offering refined risk stratification and guiding personalized therapy.

Cardiology Diabetes & Endocrinology news

High-Normal Parathyroid Hormone Levels and Mortality: Insights from the ELSA-Brasil Study on Age and Sex Differences

By MedXY 06/24/2026

Elevated parathyroid hormone at the high-normal range independently predicts greater cardiovascular and all-cause mortality, with marked sex and age disparities in a large middle-aged Brazilian cohort.

Cardiology news

Evaluating the Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates on Durable LVAD Support

By MedXY 06/24/2026

The OPTN's new status escalation policy for stable adult heart transplant candidates with durable LVADs may benefit only a small fraction of patients, as most experience complications or transplant within six years.